RIGEL PHARMACEUTICALS INC (RIGL)
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
📈 **POSITIVE** • Medium confidence analysis (71%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business